Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.

In an interview along with Ophthalmology Times , Rob Sambursky, MD, president of Verséa Ophthalmics, reviewed the company’s latest product updates. A hybrid, next-generation amniotic membrane and two diagnostic tests join Verséa’s portfolio.

Listen to the interview and read the transcript here:

Verséa Ophthalmics aims to revolutionize eye care via innovative solutions for diagnosis, treatment and management of ocular surface diseases. Their novel, point-of-care, tear-based diagnostics plus regenerative therapeutics aim in order to enhance patient care and clinical administration.

Hybrid next-generation amniotic membrane

The Biovance 3L Ocular is a triple-layed decellularized, dehydrated human amniotic membrane. Despite having 3 layers, the particular membrane is 45 microns thick plus does not feature a ring, unlike competitors. It was designed for easier handling and increased patient comfort.

Diagnostic testing


Developed in exclusive partnership with AXIM Biotechnologies, Verséa’s point-of-care lab-testing platform consists of a portable multifunctional digital go through and two specific tear-based quantitative biomarker tests to diagnose ocular surface disease rapidly, accurately, and non-invasively. Both tests take 10 minutes or less.

Allergen-specific immunoglobulin E test

Immunoglobulin E (IgE)testing helps to differentiate between allergic conjunctivitis from other forms of conjunctivitis. Because IgE is really a biomarker for allergic conjunctivitis, testing for it can remove the guesswork from the diagnosis.

The level of IgE found in tear fluid increases correlatively with the severity of sensitive response. This may be helpful with regard to clinicians in order to provide an appropriate solution to their patients.

“I like to think I’m a good cornea specialist, but despite that, it is really relatively impossible in order to differentiate mild, allergic conjunctivitis from dry eye, and it can be really challenging to differentiate an acute allergic conjunctivitis from viral conjunctivitis, ” said Sambursky. “So this test will be incredibly helpful. ”

Quantitative lactoferrin test

Measuring ocular lactoferrin as a biomarker has been the standard option regarding assessing the secretory function of the lacrimal gland. This test identifies patients along with low lactoferrin, which suggests the particular patient has an aqueousdeficient dried out condition plus allows intended for clinical differentiation from evaporative dry eye disease (DED).

At the end of the day, the goal will be to elevate care to get patients.

“Well, I think that from a diagnostic standpoint, it’s really allowing more personalized medicine, ” said Sambursky. “I think the more information the clinician has, the more targeted the therapy can be. And ultimately, that should be our goal to match the treatment with the condition. ”

“And then from your amniotic membrane layer perspective, it can part associated with the continuum. When we have very advanced ocular surface illness, we want to be able to apply the particular best possible therapeutic intervention. And in this particular case, all of us think that we have one of the best amniotic membranes to help heal those complex, non-healing persistent epithelial defects that you see with advanced ocular surface disease, ” Sambursky concluded.

Leave a Reply

Your email address will not be published. Required fields are marked *